Psoriasis in France and Associated Risk Factors: Results of a Case-Control Study Based on a Large Community Survey

Abstract

Background: Risk factors for psoriasis have been identified. Objective: To precisely define these associated factors. Methods: A survey was conducted using a questionnaire on a representative sample of the French population. A case-control study was conducted. Cases were persons who declared having had psoriasis during the previous 12 months. For each case, 3 matched controls were selected. Cases and controls were compared using univariate and multivariate analyses. Results: The questionnaire was filled out and returned by 6,887 (68.9%) of 10,000 subjects aged 15 years and over; 356 cases were identified. In multivariate analysis, a higher body mass index, current and former smoking habits and β-blocker intake were independently associated with a higher risk of psoriasis; intake of statins was associated with a decreased risk (p < 0.05). Conclusions: We confirmed the association of overweight, smoking habits and β-blocker intake with psoriasis and reported a decreased risk associated with statin intake.

Clinical and Epidemiological Features of Psoriasis in Patients Visiting Lumbini Medical College

“…As many as 15.5% of psoriasis patient develop psoriatic arthritis. 2,4,5 There are many treatment options for this disease namely topical, systemic, phototherapy and biological agents. The outcome of the treatment may differ in different individuals.…”

“…One should understand that the treatment is a control rather than cure. [3][4][5][6] The current study presents the clinical and epidemiological features of psoriatic patients attending the dermatology Outpatient department of Lumbini Medical College Teaching Hospital, which is a 700 bedded multi-specialty hospital in the semiurban area of Lumbini, Nepal.…”

Untitled

“…Various potential risk factors includes smoking, alcohol consumption, trauma, infections, endocrine factors, stressful life events, as well as exposure to drugs such as Beta blockers, Angiotensin Converting Enzyme Inhibitors(ACEI), antimalarials, Non Steroidal Anti-Inflammatory Drugs (NSAID), lithium, Interferons, as well of the acute withdrawal of systemic or potent topical corticosteroids [29][30][31][32][33] . Various case control and cross over studies shows that Beta Blockers as a major aggravating factor in patients who were hospitalized with psoriasis vulgaris 34,35,[36][37] .…”

“…The mechanism for the exacerbation of psoriasis with β blocker use is thought to be related to a blockade in the activation of the messenger system of cyclic adenosine 3' 5'-cyclic monophosphate, results in decreased intracellular concentrations of calcium which in turn causes an accelerated proliferation of keratinocytes or polymorph nuclear leukocytes, both of which may play a role in inducing psoriasis [37][38][39][40] .…”

Psoriasis and cardiovascular disease: epidemiology, mechanisms, and clinical implications

“…Hypertension screening is recommended every 2 years in adults, with a blood pressure target of less than 120/80 mmHg. The US Preventive Services Task Force also includes screening every year for those with systolic blood pressure of 120-139 mmHg or diastolic blood pressure of [80][81][82][83][84][85][86][87][88][89] …”